Barbara Ann Karmanos Cancer Institute

The Barbara Ann Karmanos Cancer Institute is a non-profit organization headquartered in Detroit, Michigan, dedicated to cancer research, patient care, and education. Its mission is to lead in transformative cancer care, research, and education through courage, commitment, and compassion, with a vision for a world free of cancer. The institute is affiliated with the Wayne State University School of Medicine.

As one of 57 National Cancer Institute-designated comprehensive cancer centers in the United States, Karmanos provides a wide array of services including comprehensive cancer treatment, extensive research programs, and educational initiatives. It operates one of the nation's largest clinical trials programs, offering patients access to over 250 treatments and conducting approximately 800 cancer-specific scientific investigations and clinical trials annually. The institute serves metropolitan Detroit and extends its reach across Michigan and northern Ohio through 18 treatment locations.

In recent leadership news, Boris C. Pasche, M.D., Ph.D., FACP, was appointed President and CEO in August 2023, also serving as chair of the Department of Oncology at Wayne State University School of Medicine. Karmanos has recently expanded access to groundbreaking targeted radiopharmaceutical therapies and became the first independent cancer center to treat Hemophilia B with new gene therapy in April 2026. The institute has also been recognized with multiple Women's Choice Awards for cancer care and patient experience in 2024 and 2025, and continues to expand its network, opening its 17th clinic in Dearborn in January 2025. As part of McLaren Health Care, Karmanos is positioned as the largest provider of cancer care and research in Michigan.